Biotechnology

Aerovate Therapeutics

Renaissance Technologies Increases Holdings in Aerovate Therapeutics

Aerovate Therapeutics Announces Dividend of $2.40

Aerovate Therapeutics released FY2025 Q1 earnings on April 25, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.0405

Aerovate Reports Q1 2025 and Announces Restructuring Plans

Aerovate Therapeutics Inc Reports Quarterly Financial Results for the Quarter Ending December 31

Aerovate Therapeutics Inc Expected Loss of $0.25 per Share, Analyst Rating Hold

Aerovate Therapeutics released FY2024 Annual Earnings on February 24, 2025 (EST), with actual revenue of USD 0 and EPS of USD -85.2622

Aerovate Therapeutics released FY2024 Q4 earnings on February 24, 2025 (EST), with actual revenue of USD 0 and EPS of USD -6.6423

Aerovate Therapeutics released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of USD 0 and EPS of USD -79.0391

Aerovate Therapeutics released FY2024 Q3 earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -19.6891

Termination fees for the transaction between Aerovate Therapeutics and Jade

Aerovate Therapeutics released FY2024 Semi-Annual earnings on August 12, 2024 (EST), with actual revenue of USD 0 and EPS of USD -58.7615

Aerovate Therapeutics released FY2024 Q2 earnings on August 12 (EST) with actual revenue of USD 0 and EPS of USD -30.1545

Aerovate Therapeutics Inc - Strategic Alternatives Review

Aerovate Therapeutics Inc: Decided to implement employee reduction measures on June 25th.

Holzer & Holzer, LLC Investigates Aerovate Therapeutics, Inc. for Possible Violation of Federal Securities Laws

Aerovate Therapeutics Inc: Goldman Sachs downgrades rating to Neutral

Aerovate Therapeutics Inc: BTIG downgrades from Buy to Neutral

Aerovate Therapeutics' research did not meet the primary endpoint

Aerovate Therapeutics released FY2024 Q1 earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -29.1954

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap